Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis
chronic-phase CML patients could potentially increase molecular responses and therefore
treatment discontinuation probabilities in these patients. We propose an Open-Label Phase
Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis
Chronic Phase-Chronic Myeloid Leukemia Patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica